US health regulators last month allowed adults to be injected intradermally, meaning between the layers of the skin rather than under the skin, in an effort to address low vaccine stocks.
Content of the article
This alternative intradermal dosing regimen will allow health care providers to administer up to five times the number of vaccine doses per vial of vaccine. The NIH trial will enroll 200 previously unvaccinated people between the ages of 18 and 50 at eight U.S. research sites. Nearly 20,000 cases of monkeypox have been reported in the United States since May, when a major global outbreak began in countries where the virus is not endemic, according to government figures. (Reporting by Khushi Mandowara; Editing by Vinay Dwivedi)
